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Abstract
The extracellular matrix (ECM) is abnormal in breast tumors and has been reported to con-
tribute to breast tumor progression. One factor, which may drive ongoing matrix synthesis in
breast tumors, is the loss of stromal caveolin-1 (cav-1), a scaffolding protein of caveolae,
which has been linked to breast tumor aggressiveness. To determine whether loss of cav-1
results in the abnormal expression of matrix proteins, mammary glands from cav- 1-/- and
cav- 1 +/+ mice were investigated for differences in expression of several ECM proteins. In
addition, the presence of myofibroblasts, changes in the vessel density, and differences in
duct number and size were assessed in the mammary glands of both animal models. Using
immunohistochemistry, expression of fibronectin, tenascin-C, collagens and αSMA were
significantly increased in the mammary glands of cav-1-/- mice. Second harmonic genera-
tion revealed more organized collagen fibers in cav-1 -/- glands and supported immuno-
histochemical analyses of increased collagen abundance in the glands of cav-1 -/- mice.
Analysis of the ductal structure demonstrated a significant increase in the number of pro-
liferating ducts in addition to significant increases in the duct circumference and area in cav-
1 -/- glands compared to cav- 1 +/+ glands. Differences in microvessel density weren’t
apparent between the animal models. In summary, we found that the loss of cav-1 resulted
in increased ECM and α-SMA protein expression in murine mammary glands. Furthermore,
we found that an abnormal ductal architecture accompanied the loss of cav-1. These data
support a role for cav-1 in maintaining mammary gland structure.
Introduction
Caveolin-1 (cav-1) is the main structural protein of caveolae [1], 50-100nm sized invaginations
in the plasma membrane [2], responsible for macromolecular transcytosis [3] and regulation
of signal transduction [4, 5]. Cav-1 has been found to be highly expressed in mesenchymal
cells including adipocytes, endothelial cells and smooth muscle cells [4] and has been reported
to act as a tumor suppressor [6, 7]. In breast cancer, cav-1 is frequently down regulated in
fibroblasts of patient breast tumors [8] and has been associated with a more aggressive tumor
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signature. For example, reduced stromal expression of cav-1 has been associated with a poor
prognosis [9, 10], decreased disease-free survival [11], tumor invasiveness [11], lymph node
metastases [10], and hormone receptor status [10] in patients with breast cancer. In addition,
the loss of stromal cav-1 has also been reported to be a prognostic indicator for early breast
tumor recurrence [11]. Mammary glands of cav-1-/- mice have been shown to possess regions
of hyperplasia [12], implicating that the loss of stromal cav-1 results in aberrant tissue architec-
ture. In addition, cav-1-/- mice crossed with tumor prone MMTV/PyMT mice were reported
to have an accelerated appearance of dysplastic foci in mammary glands [13] and were later
shown to have an increased number of lung metastases [14]. Together, these studies indicate
that the loss of cav-1 is an important driver of breast tumor progression. Although recent
efforts have been aimed at understanding the contribution of cav-1 toward tumor growth, it
remains unknown whether the loss of cav-1 is associated with alterations in the stromal archi-
tecture of the gland, a phenomenon that has been extensively reported to accompany breast
tumor progression.
All cells in the body reside in a supportive structure known as the extracellular matrix
(ECM), a non-cellular entity that acts as a scaffold to maintain 3-dimensional (3D) tissue
architecture. The ECM actively participates in numerous cellular activities including cell adhe-
sion, survival, proliferation, differentiation and migration in addition to providing mechanical
support to overlying cells [15]. Locally resident cells, such as fibroblasts secrete the compo-
nents that make up the ECM of which the main constituents include collagens and glycopro-
teins such as fibronectin [16–18]. Production and modification of these ECM proteins are
further enriched following fibroblast activation into a proliferative, contractile phenotype.
Referred to as myofibroblasts or carcinoma-associated fibroblasts (CAFs), these cells partici-
pate in breast tumorigenesis through secretion of cytokines and growth factors and an exag-
gerated production of ECM proteins [19].
Alterations in ECM composition have been attributed to initiating tumorigenesis [20]. In
breast carcinomas, mammographically dense breast tissue is commonly linked to an increased
risk of developing breast cancer [21–23]. In particular, it has been shown that total collagen
increases with increasing breast density as defined using radiographic measures [24, 25]. Not
surprising, several groups have shown a correlation between increased collagen density and
breast tumor invasion and metastasis [26–30]. In addition, the glycoprotein fibronectin is also
aberrantly expressed in breast tumors and has been associated with tumor initiation [31], inva-
sion and metastasis [32] and therapy resistance [33]. Interestingly, it was found that collagen
density and organization in addition to increased fibronectin expression were upregulated in
the dermis of cav-1 -/- mice [34]. Furthermore, stabilization of fibronectin fibrils in the ECM
was reported to be a result of RNAi-mediated inhibition of cav-1 in fibroblasts [35]. Together,
these reports suggest that abnormal matrix protein expression in breast tumors drives disease
progression and that caveolin-1 may be an important regulator of matrix protein expression.
Given the roles for the ECM in breast tumor progression and their association with cav-1
expression, we tested the hypothesis that the loss of cav-1 in murine mammary glands was
associated with altered expression of stromal ECM proteins and was additionally responsible
for disrupting healthy ductal architecture. As such, the goal of this project was to determine
whether absence of caveolin-1 resulted in tissue and ductal abnormalities indicative of the
early events of breast tumorigenesis. In this paper, we report that the loss of cav-1 resulted in
increased expression of the matrix proteins fibronectin, tenascin-C, and collagen I. In addi-
tion, expression of alpha-smooth muscle actin (αSMA), a well-characterized marker for myofi-
broblasts [36], was increased in the myoepithelial compartment of mammary glands from cav-
1 deficient animals. Furthermore, ductal architecture was disrupted in the mammary glands of
cav-1 deficient animals. This was evidenced from the presence of an increased number of
Caveolin-1 and mammary gland architecture
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ducts in addition to ducts that exhibited a larger area and circumference and a higher prolifer-
ation index. Overall, our results support a role for the loss of cav-1 on altering the stromal
composition and ductal architecture of the murine mammary gland. Combined, these results
have important implications for a better understanding of how cav-1 participates in the regula-
tion of normal breast tissue architecture and warrants further investigation to determine
whether the reduced expression of this protein participates in the early stages of
tumorigenesis.
Methods
Animal model
Nulliparous female Mus musculus C57BL/6J wild-type control (cav-1 +/+) and B6.Cg-Cav1
homologous knockout (cav-1 -/-) animals were obtained from Jackson Laboratories, Bar Har-
bor, ME. All animals were received between 4–6 weeks of age and were allowed to acclimate to
their new colonies for 3–4 weeks before undergoing necropsy for mammary gland isolation.
Procedures on animals were performed in accordance with an approved GA-PCOM IACUC.
Mammary gland harvest and tissue fixation
Prior to mammary gland collections, animals were euthanized using CO2 asphyxiation. Ani-
mals were subsequently subjected to necropsy wherein the inguinal mammary glands were col-
lected from six animals in each group. Immediately post-harvest, glands were placed in 5–10
mL of 10% neutral buffered formalin (Sigma-Aldrich) for 48–72 hours. Tissues were processed
at the Research Pathology, Winship Cancer Institute, Emory University Medical Center,
Atlanta, Georgia). Tissues were paraffin block embedded (FFPE) and were sectioned at 5 μm
slices onto standard, charged glass slides using an automated microtome.
Immunohistochemistry. Slides were de-paraffinized in 100% xylene for 10-minutes.
The slides were dehydrated by placing in 100% ethanol for 6-minutes followed by 3-minute
incubations each of 95%, 75%, and 50% ethanol. In order to cleave epitopes from sections of
tissue, slides were incubated in 10 mM sodium citrate solution (pH adjusted to 6.0) at 95˚C for
10-minutes, and then allowed to cool to room temperature for 20-minutes. Once slides were
cooled, the endogenous enzyme activity of tissues was blocked using 200 μL dual peroxidase
and alkaline phosphatase blocking reagent (Dako EnVision Kit) for 5±1-minutes in a humidi-
fied chamber. After a brief wash in deionized water, the slides were incubated in 10% donkey
serum (EMD Millipore) for 1 hour. After blocking, the primary antibody was prepared in 1%
donkey serum in PBS. Antibodies used include: 1:150 anti-fibronectin (Abcam); 1:50 anti-
tenascin-C (Abcam); 1:100 anti-αSMA (Abcam); and 1:25 CD31 (Abcam). Slides were allowed
to incubate for 1 hour in a humidified chamber at room temperature or at 4˚C overnight. Fol-
lowing prescribed incubations, slides were washed briefly with diH2O. Approximately 200 μL
of anti-rabbit labeled polymer (Dako EnVision Kit) was applied to the tissues and incubated at
room temperature in a humidified chamber for 30 minutes. Immediately after secondary incu-
bation, slides were briefly rinsed with diH2O then placed in 1X PBS for 5-minutes. Approxi-
mately 200 μL of DAB+ Chromogen solution (Dako) was added to tissues and incubated for 5
±1-minutes. Slides were carefully rinsed with diH2O and briefly cleared by 100% xylene dip
before proceeding to hematoxylin and eosin (H&E) staining or coverslip mounting. For H&E
staining, slides were submerged in Harris’s Hematoxylin (Sigma-Aldrich) for 2 to 2.5-minutes.
Next, slides were carefully washed in running tap water followed by 2 brief dips in differentia-
tion solution (0.25% hydrochloric acid in 70% ethanol). The slides received a second tap water
rinse before a 60-second submersion in a bluing solution (4.5 mg calcium carbonate dissolved
in 500 mL of tap water and adjusted pH 9.4). Slides were removed from the bluing solution
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and placed in a bath of 95% ethanol for 30 seconds. Slides were incubated in Alcoholic Eosin Y
(Sigma-Aldrich) for 0.5 to3-minutes. Excess eosin was removed with 1 dip in 95% ethanol and
dehydrated in 2 washes of 95% ethanol at 5-minutes each. Sections were mounted with 1–2
drops of aqueous, permanent mounting media (Dako) and visualized using an Olympus BX43
upright microscope at 10, 20 and 40x magnifications. Images were captured using the attached
Olympus DP73 color camera and processed using Olympus cellSens Entry software. Six repre-
sentative stained sections for fibronectin, tenascin-C and αSMA from each animal model at
20x magnification were analyzed for the abundance of protein expression using the IHC
toolbox in Image J.
Picrosirius red staining. Analysis of the expression of stromal collagen I was achieved by
picrosirius red (PSR, Abcam) staining. Sections were de-paraffinized and dehydrated using the
steps previously described. Slides were incubated in PSR for 1 hour followed by regressive
staining in 2 brief dips in 5% acetic acid solution. Slides were then dehydrated in two washes
of 95% ethanol. All slides were mounted using Eukitt’s Mount (Sigma-Aldrich) and cover-
slipped. Sections were visualized using an Olympus BX43 upright microscope at 10, 20 and
40x magnification. Images were captured using the attached Olympus DP73 color camera and
processed using Olympus cellSens Entry software. Six representative PSR stained sections of
each animal model at 20x magnification were analyzed for the abundance of stromal collagens
using the IHC toolbox in ImageJ.
Intensity measurements. Representative images of each animal model and stain (fibronec-
tin, tenascin-C, αSMA, and PSR) were selected. A total of 6 images at 10x magnification from
each stain was analyzed. DAB-associated brown or PSR-associated red staining within each
image was automatically isolated using IHC Toolbox plugin for ImageJ. Using ImageJ, the
resulting images were converted to a 16-bit image and thresholded to avoid the inclusion of
counterstain. The mean grey value was obtained from the resulting images. This value yielded a
single number that represented the total stain density divided by the total number of pixels.
Second harmonic generation. Collagen organization was analyzed in cav 1 -/- and cav 1
+/+ mammary glands using multiphoton microscopic detection of second harmonic genera-
tion (SHG). The acquisition of SHG images was achieved utilizing a Leica TCS SP8 Confocal
Laser Scanning Microscope with a 63x oil immersion objective. Photon excitation was induced
by a Coherent Chameleon Ultra-II sapphire laser generator while activity was received by 2
PMT and 2 HyD detectors. The multiphoton laser was initially tuned to 800 nm and detectors
trained to receive SHG signals between 400–425 nm. Images were captured and processed
using Leica LAS X software, with 1x line accumulation, 8x line average, 1x frame average and
2x frame accumulation. Multiple line averages were used in order to increase the resolution of
the images and two times frame accumulation was used to increase the visibility of the fibers
overall. A total of 5 images per animal model were analyzed.
Microvessel density. Differences in vessels numbers were analyzed using a 1:25 dilution
of CD31 (Abcam). Slides from cav-1 -/- and cav-1 +/+ glands were prepared for immunohis-
tochemistry and imaged as previously described. Vessels in 20x magnified images were manu-
ally enumerated from 3–6 non-overlapping images each in 5–6 slides from cav-1 -/- and cav-1
+/+ glands.
Ductal measurements. Using ImageJ software, mammary gland ducts and surrounding
stroma were analyzed in 10x images from cav 1+/+ and cav 1-/- mammary gland sections
stained with αSMA and H&E. Careful to exclude vascular structures, which were identified by
morphological differences including the presence of a tunica media and flattened, elongated
cells and nuclei in place of columnar-like cells nuclei bordering the lumen, ducts were counted
in representative images (n = 30). To analyze the ductal area and circumference, ducts from
the same images used for ductal counts were measured (n = 30). To maintain consistency,
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only ducts with an intact lumen were analyzed. To examine the ductal circumference, a vector
was drawn using Image J (NIH) around the periphery of the myoepithelial compartment. To
investigate the ductal area, vectors were drawn using Image J (NIH) to encompass the myoe-
pithelial and luminal compartments. The total area encompassed within the vector drawn
around the lumen was subtracted from the vector drawn around the myoepithelial
compartment.
Proliferation analyses
To determine differences in the proliferation of ductal epithelial cells, slides from cav-1 -/- and
cav-1 +/+ glands were immunostained with a 1:200 dilution of ki67 (Abcam and Bioss) using
methods previously described. Three slides from each animal model with 3–6 images per slide
were quantified for differences in ki67 staining using the Cell Counter tool in ImageJ (NIH).
Statistical analyses. All measurements were screened for Gaussian distribution before
eliminating the outliers (Q = 1%). Analyses of ductal numbers, area, circumference, microves-
sel density and ECM/myofibroblast markers in cav-1 -/- glands were analyzed for differences
against the cav-1 +/+ control glands using student’s t-test in GraphPad Prism v6. All results
are reported as the mean ± the SD or SEM. Statistical significance was assigned at p0.05 (),
p0.01 (), p0.001 (), and p0.0001 ().
Results
Fibronectin is upregulated in cav-1 -/- mammary glands
Increased fibronectin expression has been shown to both accompany breast tumorigenesis and
support breast tumor progression [32, 37–39]. Furthermore, siRNA of cav-1 in fibroblasts has
been shown to result in excess fibronectin matrix deposition [35]. In light of these studies, we
sought to first determine whether the loss of cav-1 resulted in increased mammary gland fibro-
nectin expression. Cav-1 -/- glands were generally observed to have prominent increases in the
density and abundance of fibronectin (Fig 1A). Fibronectin was located most abundantly in the
stroma immediately surrounding the ducts (peri-ductal) and was observed to occupy regions
within the adipose stroma as well (Fig 1A). In addition, fibronectin expression was also observed
in the epithelial cells lining the ducts (Fig 1A). Cav-1 +/+ glands were observed to contain fibro-
nectin fibers in the peri-ductal and adipose stroma (Fig 1A). Similar to cav-1 -/- glands, some
fibronectin expression was also apparent in the epithelial cells lining the ducts (Fig 1A). Overall,
the abundance of fibronectin in cav-1 +/+ glands was considerably less than that which was
observed for cav-1 -/- glands (Fig 1A). Analyzing the percent coverage of fibronectin, it was
found that fibronectin expression was 2-fold more abundant in the mammary glands of cav-1
-/- mice as compared to cav-1 +/+ mice, 26.9% versus 13.6% (p = 0.0206), respectively (Fig 1B).
Analyzing differences in staining intensity, it was found that cav-1 -/- glands exhibited a signifi-
cantly greater degree of staining intensity for fibronectin than cav-1 +/+ glands (Fig 1C), sup-
porting visual and quantitative data that fibronectin staining is more abundant in cav-1 -/-
glands. These results demonstrate that the loss of cav-1 promotes the increased expression of
peri-ductal and adipose stromal fibronectin in murine mammary glands and further indicates
that the overall abundance of fibronectin is greater in cav-1 -/- glands.
Tenascin-C is upregulated in cav-1 -/- mammary glands
Tenascin-C is a stromal protein that has been reported to be more highly expressed in invasive
breast carcinomas [40] and has also been shown to support lung metastatic niche formation
from breast cancer cells [41]. Although tenascin-C appears to have a prominent role in breast
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tumor invasion and metastasis, we sought to determine whether the loss of cav-1 promoted
increased mammary gland expression of tenascin-C. This is in part due to a recent report that
demonstrated that stromal deposition of tenascin-C from fibroblasts co-cultured with breast
cancer cells occurred exclusively in the presence of a pre-established cell-derived fibronectin
matrix [42]. Results show that cav-1 +/+ glands demonstrated some tenascin-C staining which
was primarily confined to the peri-ductal stroma (Fig 2A). Cav-1 -/- glands, on the other hand,
exhibited tenascin-C, which was not only expressed in the peri-ductal stroma but also in the
adipose stroma (Fig 2A). In addition, tenascin-C also appears to be expressed in some of the
stromal cells in cav-1 -/- and cav-1 +/+ glands, with more extensive expression in cav-1 -/-
glands (Fig 2A). Comparing the expression of tenascin-C between the two animal models, it
was found that tenascin-C was more than 2 fold higher in cav-1 -/- glands in comparison with
cav-1 +/+ glands, 9.2% and 4.4%, respectively (Fig 2B). Additionally, cav-1 -/- glands exhibited
Fig 1. Fibronectin expression is upregulated in cav-1 -/- mammary glands. (A) Immunohistochemistry of
fibronectin expression in cav-1 +/+ and cav-1 -/- glands at low and high magnification. Results demonstrated
an increased abundance fibronectin fibers surrounding the ducts and in the adipose stroma of cav-1 -/-
glands. Fibronectin expression was also localized to the epithelial cells (red arrows) of the ducts in both cav-1
+/+ and cav-1 -/- glands. (B) The percent expression of fibronectin was significantly higher in cav-1 -/- glands
compared to cav-1 +/+ glands. (C) The intensity of fibronectin staining was significantly higher in cav-1 -/-
glands compared to cav-1 +/+ glands. Scale bars are 50 μM and 20 μM in low and high magnification images,
respectively. *p0.05. Fn: fibronectin. Results are reported as the mean ± the SEM.
doi:10.1371/journal.pone.0172067.g001
Caveolin-1 and mammary gland architecture
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a significantly greater degree of staining intensity for tenascin-C than cav-1 +/+ glands (Fig
2C). These results indicate that loss of cav-1 upregulates tenascin-C expression primarily in
the stroma surrounding and in proximity to the ducts in addition to stromal and epithelial
cells and also indicates that the overall abundance of tenascin-C is greater in cav-1 -/- glands.
Collagen abundance and organization is increased in cav-1 -/- mammary
glands
Collagen, the most abundant ECM protein in the body, including the breast, has been reported
to be increased in the dermis of cav-1 -/- mice [34]. To determine whether collagen is similarly
upregulated in the mammary glands of cav-1 -/- mice, immunohistochemistry for collagen
Fig 2. Tenascin-C expression is upregulated in cav-1 -/- mammary glands. (A) Immunohistochemistry of
tenascin-C expression in cav-1 +/+ and cav-1 -/- glands at low and high magnification. Results demonstrated
an increased expression of tenascin-C in the peri-ductal and adipose stroma in cav-1 -/- glands. This is in
contrast to cav-1 +/+ glands where tenascin-C expression is expressed in the peri-ductal stroma and to a
lesser extent in the adipose stroma. Tenascin-C was also expressed in the stromal cells in cav- 1-/- and cav-1
+/+ glands (red arrows), albeit with a greater proportion of positive cells in cav-1 -/- glands. (B) The percent
expression of tenascin-C was significantly higher in cav-1 -/- glands compared to cav-1 +/+ glands. (C) The
intensity of tenascin-C staining was significantly higher in cav-1 -/- glands compared to cav-1 +/+ glands.
Scale bars are 50 μM and 20 μM in low and high magnification images, respectively. *p0.05, **p0.01. Tn-
C: tenascin-C. Results are reported as the mean ± the SEM.
doi:10.1371/journal.pone.0172067.g002
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was performed using picrosirius red (PSR) which largely detects the birefringence of co-aligned
fibers of collagen I. Images from PSR stained slides indicate that glands from cav-1 -/- animals
possess extensive stromal expression of collagen in comparison to cav-1 +/+ glands, which
exhibit markedly less stromal collagen (Fig 3A). Here, the collagen fibers in cav-1 -/- glands
are more densely packed and thicker, especially in the peri-ductal stroma, in comparison to
cav-1 +/+ glands, which possess thinner fibers primarily confined to the peri-ductal stroma (Fig
3A). These visual inspections were supported by quantitative analyses wherein loss of cav-1
resulted in an average collagen expression of 8.5% as opposed to 3% in cav-1 +/+ animals (Fig
3B), indicating that collagen is almost 3 fold upregulated in the mammary glands of cav-1 defi-
cient animals. Furthermore, analysis of staining intensity revealed that cav-1 -/- glands exhibited
a significantly greater degree of staining intensity for PSR collagen than cav-1 +/+ glands (Fig
3C), supporting quantitative analyses of overall collagen expression and abundance.
To further support findings from PSR data, we sought to examine the abundance and orga-
nization of collagen in cav-1 -/- and cav-1 +/+ glands using SHG, a powerful imaging modality
which identifies collagen fibers in unstained tissue sections. Using this technique, we were able
to which capture both type I and type II aligned collagen fibers [43]. Similar to PSR stained
sections, glands from cav-1 -/- animals demonstrated an increase in collagen density that was
further accompanied by a distinguishable organization of the collagen fibers (Fig 3D). With
regard to organization, cav-1 -/- glands presented with large collagen bundles that were not
only aligned (arrows), but also projected into the adipose stroma away from ducts (Fig 3D). In
cav-1 +/+ glands, expression of collagen fibers were sparse and were much thinner in compari-
son to cav-1 -/- glands (Fig 3D). These data demonstrate that loss of cav-1 results in increased
expression of organized stromal collagens.
αSMA is upregulated in cav-1 -/- mammary glands
αSMA is the well-characterized marker of myofibroblasts or CAFs [36], activated fibroblasts
that participate in wound healing and tumorigenesis [44]. It’s been reported that cav-1 defi-
cient fibroblasts have properties similar to breast CAFs [45]. As such, we sought to determine
whether αSMA positive stromal cells were upregulated in cav-1 -/- glands. As expected, αSMA
was observed to be predominantly localized in the myoepithelial compartment adjacent to the
ducts in cav-1 -/- and cav-1 +/+ glands (Fig 4A). Some αSMA staining was observed in stromal
cells adjacent to the ducts and was additionally found in cells occupying the adipose stroma in
cav-1 -/- and cav-1 +/+glands (Fig 4A). Although there were no discernible differences in αSMA
expression between cav-1 -/- and cav-1 +/+ glands, image analysis yielded an average αSMA ex-
pression in cav-1 -/- glands at 12.9% compared to 5.3% in cav-1 +/+ glands (Fig 4B). As expected
based on visual inspection and quantitative analyses of overall expression, cav-1 -/- glands exhib-
ited a significantly greater degree of staining intensity for αSMA than cav-1 +/+ glands (Fig 4C).
Data on stain intensity and overall coverage of tested proteins in cav-1-/- and cav-1 +/+ glands
are available in S1 File. These results demonstrate that the loss of cav-1 -/- promotes the increased
expression of myoepithelial and stromal cell αSMA, a finding which is presumably due to in-
creased ductal numbers in cav-1 -/- glands.
Microvessel density is similar in cav-1 -/- and cav-1 +/+ glands
Increased vascularization has been reported to occur in response to ECM protein expression
[16, 42, 46]. Given the abundance of ECM proteins observed in cav-1 -/- glands, we sought to
determine whether the loss of cav-1 resulted in increased vascularization in the mammary
glands. Following immunohistochemistry staining for the endothelial marker CD31 and enu-
meration of vessels, it was found that there were no differences in the microvessel density
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between the two animal models (Fig 5A and 5B). In fact, there was an average of 1.8 vessels per
slide in both cav-1 -/- and cav-1 +/+ glands (Fig 5B). Data on microvessel density in cav-1-/-
and cav-1 +/+ glands are available in S3 File. indicating that neither the loss of cav-1 nor the
increased ECM protein expression observed in cav-1 -/- glands promote tissue vascularization.
Ductal architecture is aberrant in cav-1 -/- mammary glands
To determine whether the loss of cav-1 resulted in alterations to the ductal architecture, we
investigated differences in duct number, circumference and area. Not only were average duct
Fig 3. Collagen I expression and organization are upregulated in cav-1 -/- mammary glands. (A) PSR staining for collagen I in cav-1 +/+ and cav-1
-/- glands at low and high magnification. Imaging demonstrates extensive expression of collagen I in the adipose stroma and in the peri-ductal region of
cav-1 -/- glands. The collagen I fibers appear dense and tightly packed in cav-1 -/- glands. In contrast, overall collagen I expression is considerably lower
in cav-1 +/+ glands with fibers being predominantly located to the peri-ductal region. Here, fibers are less packed and distinct fibrils are apparent. (B) The
percent expression of PSR stained collagen I was significantly higher in cav-1 -/- glands compared to cav-1 +/+ glands. Scale bars are 50 μM and 20 μM
in low and high magnification images, respectively. (C) The intensity of PSR stained collagen I was significantly higher in cav-1 -/- glands compared to
cav-1 +/+ glands. (D) Representative SHG images show an abundance of dense, thick collagen fibers in cav-1 -/- glands. Collagen fibers and fiber
bundles also appear more organized and aligned (red arrows). Cav-1 +/+ glands express comparably less collagen which presents as thin, unorganized
fibers. Scale bars are 25 μM. Col: collagen. *p0.05, **p0.01. Results are reported as the mean ± the SEM.
doi:10.1371/journal.pone.0172067.g003
Caveolin-1 and mammary gland architecture
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numbers significantly increased in cav-1 -/- versus cav-1 +/+ glands: 7.8 and 4.6, respectively,
but ducts in cav-1 -/- glands tended to be highly branched and convoluted in contrast with the
round, largely non-branched ducts of cav-1 +/+ glands (Fig 6B). In addition to these morpho-
logical differences, ducts in cav 1 +/+ glands mostly presented as single-celled columnar epi-
thelium while the cav-1 -/- glands often had ducts that were large, disorganized, multicellular,
and compacted with epithelium lacking the traditional columnar/cuboidal ductal formation,
indicative of ductal hyperplasia (Fig 6C). Next, we examined differences in ductal circumfer-
ence to support observations that cav-1 -/- ducts are larger. We also investigated ductal area
to support observations that cav-1 -/- ducts exhibit increased ductal hyperplasia. As expected,
significant increases were also observed for the average duct circumference: 267.2μm and
203.8μm (Fig 6D) and area: 8,003μm2 and 4,510μm2 (Fig 6E) in cav-1 -/- and cav-1 +/+ glands,
respectively. To examine the ductal circumference, a red vector was drawn using Image J
Fig 4. αSMA expression is upregulated in cav-1 -/- mammary glands. (A) Immunohistochemistry of
αSMA in cav-1 +/+ and cav-1 -/- glands at low and high magnification. Results demonstrated that αSMA
expressing cells are predominantly localized to the myoepithelial compartments in cav-1 +/+ and cav-1 -/-
glands. αSMA expressing cells are also observed in adipose stromal cells (arrows) in cav-1 +/+ and cav-1 -/-
glands (B) The percent expression of αSMA was significantly higher in cav-1 -/- glands compared to cav-1
+/+ glands. (C) The intensity of αSMA staining was significantly higher in cav-1 -/- glands compared to cav-1
+/+ glands. Scale bars are 50 μM and 20 μM in low and high magnification images, respectively. *p0.05.
Results are reported as the mean ± the SEM.
doi:10.1371/journal.pone.0172067.g004
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around the periphery of the myoepithelial compartment (Fig 6F). Similarly, to investigate the
ductal area, red and blue vectors were drawn using Image J to encompass the myoepithelial
and luminal compartments, respectively (Fig 6F). The total area encompassed within the vec-
tor drawn around the lumen was subtracted from the vector drawn around the myoepithelial
compartment. The area thus represents the region contained between the myoepithelial and
epithelial cells lining the lumen. Data on ductal metrics in cav-1-/- and cav-1 +/+ glands are
available in S1 File. These results indicate that cav-1 -/- ducts are not only more numerous and
branched having distinct patches of hyperplasia, but are larger than wild type cav-1 +/+ ducts.
In an effort to determine whether the aberrant ductal architecture was a result of increased
ductal epithelial cell proliferation, cav-1 -/- and cav-1 +/+ glands were stained for the prolifera-
tion marker ki67. Immunohistochemistry findings demonstrated an increased proportion of
Fig 5. Microvessel density is similar in cav-1 -/- and cav-1 +/+ glands. (A) Immunohistochemistry of
CD31 expressing endothelial cells in cav-1 +/+ and cav-1 -/- glands at low and high magnification. Results
demonstrated that vessels are apparent in both cav-1 +/+ and cav-1 -/- glands. (B) Quantification of
microvessels show no differences in the abundance of vessels in cav-1 +/+ and cav-1 -/- glands. Scale bars
are 50μM and 20μM for low and high magnification images, respectively. Results are reported as the
mean ± the SD.
doi:10.1371/journal.pone.0172067.g005
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positively stained ki67 ductal cells in cav-1 -/- as opposed to cav-1 +/+ glands (Fig 7A). To
quantify the number of proliferating ductal epithelial cells in cav-1 -/- and cav-1 +/+ glands,
Fig 6. Ductal architecture is disrupted in cav-1 -/- glands. (A) The number of ducts were enumerated in αSMA stained sections from cav-1 -/- and cav-
1 +/+ glands. Results demonstrated a highly significant average number of ducts per image in cav-1 -/- glands in comparison to cav-1 +/+ glands. (B)
Images of fibronectin stained sections illustrate the abundance of large, elongated, branched ducts (red arrows) in cav-1 -/- glands. Ducts in cav-1
+/+ glands appear small and relatively round (red arrows). Scale bars are 100μM. (C) H&E stained images of glands demonstrate the presence of stacked
ductal epithelial cells in cav-1 -/- sections, indicative of ductal hyperplasia. Cav-1 +/+ glands exhibit a continuous monolayer of ductal epithelial cells. Scale
bars are 20μM. (D) The ductal circumference, measured as the region immediately outside the myoepithelial compartment, was analyzed in αSMA stained
sections in cav-1 -/- and cav-1 +/+ glands. The ductal circumference was significantly greater in cav-1 -/- as opposed to cav-1 +/+ glands. (E) The area,
measured as the region between the myoepithelial and luminal compartment, was analyzed in αSMA stained sections in cav-1 -/- and cav-1 +/+ glands.
The ductal area was significantly greater in cav-1 -/- as opposed to cav-1 +/+ glands. (F) This image of an αSMA stained cav-1 +/+ duct illustrates the
vectors used to assign stromal and lumen outlines used to analyze ductal measurements. The red line shows the stromal border while the blue line shows
the lumen border. Scale bar is 50uM. *p0.05, **p0.01, ***p0.001. Results are reported as the mean ± the SEM.
doi:10.1371/journal.pone.0172067.g006
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ki67 expressing cells were enumerated using the Cell Counter tool in ImageJ. Results demon-
strate a statistically significant higher proportion of ki67 positive ductal epithelial cells in cav-1
-/- glands in comparison to cav-1 +/+ glands (Fig 7B). Data on the numbers of ki67 positive
cells in cav-1-/- and cav-1 +/+ glands are available in S3 File. These data suggest that the loss of
cav-1 supports an environment conducive to ductal proliferation.
Discussion
Breast cancer is a complex disease of heterogeneous origins. One mechanism that facilitates
breast tumorigenesis is decreased expression of stromal cav-1. Previous studies have shown
that downregulation of cav-1 in breast cancer has led to cancer invasion and metastasis [10, 11,
47], poor clinical outcome [48], altered therapy responses [49], and decreased progression-free
survival time [10, 11]. In addition to cav-1, altered ECM protein expression has been shown to
facilitate breast tumorigenesis. For example, increased fibronectin, collagen and tenascin-C
accompany breast tumorigenesis and participate in tumor progression, invasion and metasta-
sis [28, 29, 32, 37–41, 50–52]. Since the development and progression of breast cancer are
dependent on changes in the ECM, we sought to investigate how ECM protein expression and
organization are altered in response to the loss of cav-1. Here, we provide evidence that the
loss of cav-1 resulted in increased expression of collagens, fibronectin, and tenascin-C in addi-
tion to the myoepithelial and myofibroblast marker αSMA in murine mammary glands. In
addition, we also demonstrate that the loss of cav-1 contributes to an altered ductal architec-
ture, characterized by an increased number of ducts, which were more proliferative and hyper-
plastic and exhibited a larger circumference and area in comparison to wild-type controls.
Combined, these results support a role for the loss of cav-1 in altering mammary gland ECM
composition and ductal morphology.
Since aberrant fibronectin expression has been shown to support breast tumorigenesis, we
sought to first determine whether the loss of cav-1 increased the stromal expression of this
matrix protein. We found that fibronectin was more than 2-fold enriched in cav-1 -/- glands as
opposed to cav-1 +/+ glands and that the intensity of staining was also significantly increased
in cav-1 -/- glands. In cav-1 -/- glands, the fibronectin fibers appeared dense and widespread
throughout the adipose stromal tissue and in the peri-ductal stroma. Cav-1 +/+ glands also
exhibited fibronectin fibers in the peri-ductal stroma and adipose stromal tissue; however, the
Fig 7. Proliferation of ductal epithelial cells is increased in cav-1 -/- glands. (A) Immunohistochemistry of ki67 cells in cav-1 +/+ and cav-1 -/-
glands at low and high magnification. Results from representative images demonstrated that ki67 expressing ductal epithelial cells (arrows) are
markedly increased in cav-1 -/- glands in comparison to cav-1 +/+ glands. (B) The average number of ki67 positive cells was significantly higher in cav-
1 -/- glands in comparison to cav-1 +/+ glands. Scale bars are 20uM. **p0.01. Results are reported as the mean ± the SD.
doi:10.1371/journal.pone.0172067.g007
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abundance of these fibers was considerably less than that observed for cav-1 -/- glands. These
data support previous work showing that RNAi of cav-1 in murine fibroblasts promoted
increased matrix fibronectin deposition and decreased fibronectin degradation, a result that
was dependent on the absence of cav-1 mediated endocytosis of fibronectin [35]. Given these
findings in addition to other work demonstrating that fibronectin co-localizes with cav-1 in
lipid rafts [53], it’s likely that the increased abundance of fibronectin observed in cav-1 -/-
glands is a result of deficiencies in cav-1 mediated endocytosis of fibronectin. Although a likely
possibility, it will be necessary to validate that this mechanism not only takes place in the mam-
mary gland, but that it occurs in-vivo as well. Of interest is the examination of whether the
degree of stromal cav-1 loss coincides with increased fibronectin expression in breast tumors.
Presumably, the more severe decrease in stromal cav-1 would result in the greatest overall
increase in tumor fibronectin expression. Given the prominent roles for the loss of cav-1 and
the increase in fibronectin during breast tumorigenesis, it will be important for future work to
consider the mechanism whereby cav-1 contributes to fibronectin expression and how the two
proteins collaborate during tumorigenesis.
Similar to fibronectin, stromal collagens have been reported to participate in breast tumori-
genesis [28, 29, 51]. To investigate collagen expression patterns, we used PSR, which gives a
red birefringence signal for more cross-linked collagen (e.g. more mature) and a yellow/green
birefringence for less cross-linked collagen (e.g. less mature). Examining collagen expression
in cav-1 -/- and cav-1 +/+ glands, we observed that both cav-1 -/- and cav-1 +/+ sections
exhibited a red birefringence indicative of the presence of mature, cross-linked collagen I. Loss
of cav-1, however, correlated with an almost 3-fold increase in overall collagen I expression
and further resulted in a significant increase in staining intensity in comparison to cav-1
+/+ glands. Interestingly, the collagen I fibers were not only more abundant in the peri-ductal
and adipose stroma, but were more compact in cav-1 -/- glands as opposed to cav-1 +/+ glands
in which collagen I was primarily localized as thin distinguishable fibers in the peri-ductal
stroma. This finding is in support of work by Castello-Cros [34], who similarly observed
tightly packed collagen fibers in the dermis of cav-1 -/- mice. To determine whether collagen
fibers were more aligned in cav-1 -/- glands, a morphological feature associated with breast
tumorigenesis, we used SHG, a powerful imaging modality which enables visualization of type
I and II collagen fibers in unstained tissue sections [43]. Using SHG, we demonstrated that col-
lagen fibers were sparse and primarily localized to small regions immediately surround the
ducts in cav-1 +/+ glands. In cav-1 -/- glands, collagen fibers were not only more abundant but
also appeared linearized, a finding which has previously been found to increase matrix stiffness
and sequestration of tumor-promoting cytokines in addition to supporting breast tumor pro-
gression [27, 28, 54]. It’s likely that collagen fiber organization accompanies increased collagen
density as Fraley et al [55] used 3D self-assembling collagen gels to demonstrate that increased
collagen density not only supported collagen fiber alignment, but also supported cell motility.
As such, it’s possible that both the increased density and organization of collagens in cav-1 -/-
glands is setting up a supportive environment for aberrant cell behaviors potentially leading to
tumorigenesis. Indeed, it’s well known that women with increased collagen density have a
higher risk of developing breast cancer [22, 23, 56]. It will be important for future studies to
determine whether the increased collagen density and organization resulting from the loss of
cav-1 contributes to abnormal mammary cell behaviors.
In addition to fibronectin and collagen, we also investigated the expression of tenascin-C, a
matrix protein shown to support breast tumor invasion [40] and lung metastatic niche forma-
tion [41]. As expected, tenascin-C was upregulated in cav-1 -/- glands as analyzed from overall
abundance and intensity of staining with expression localized to the peri-ductal and adipose
stroma. In cav-1 +/+ glands, tenascin-C staining was primarily confined to the peri-ductal
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stroma. In prostate cancer, it has been shown that RNAi of cav-1 in benign prostatic myofibro-
blasts promotes tenascin-C gene expression [57], supporting a role for reduced or absent stro-
mal cav-1 in increased tenascin-C. Although it’s unknown as to mechanism responsible for
upregulated tenascin-C in response to cav-1 deficiency, it’s been shown that tenascin-C is
deposited in cell-derived ECM in response to a pre-established fibronectin matrix [42]. It’s
possible that the presence of excess stromal fibronectin in cav-1 -/- glands acts as a supportive
scaffold for the deposition of tenascin-C. It’s also possible that like fibronectin, the loss of cav-
1 prevents endocytosis of tenascin-C. Given that the abundance of tenascin-C was markedly
less than that observed for fibronectin, one or more mechanisms may be responsible for its
increased expression in cav-1 -/- glands. Further work will be necessary to delineate a mecha-
nism(s) responsible for the upregulated tenascin-C expression.
αSMA is the well-characterized marker of myofibroblasts or CAFs [36], activated fibro-
blasts which not only deposit copious ECM proteins and remodel these but also participate in
tumorigenesis [44, 58]. Furthermore, it has been reported that cav-1 deficient fibroblasts have
properties similar to breast CAFs [45]. As such, we expected to observe an increased abun-
dance of αSMA expressing cells in the adipose stroma of cav-1 -/- glands, a finding which
wasn’t supported. Despite a more than 2-fold increase in abundance and a significant increase
in staining intensity for αSMA in cav-1 -/- glands, there were no detectable differences in
staining patterns between the two tissues. For instance, we found that αSMA was primarily
localized to the myoepithelial compartment, an expected observation given the presence of
smooth muscle cells surrounding the ducts, in both animal models. In addition, αSMA was
expressed in adipose stromal cells of both animal models. A possible explanation for our dis-
cordant observations is the presence of additional ducts that were observed in cav-1 -/- glands.
Given the increased number of ducts and thus myoepithelial cells surrounding these ducts, it
would be expected that αSMA would be concordantly increased in cav-1 -/- glands.
ECM proteins, especially fibronectin, collagen I, and tenascin-C, have been reported to pro-
mote angiogenesis [16, 42, 46, 59]. Given the abundance of these ECM proteins observed in
cav-1 -/- glands, we expected that the microvessel density would be correspondingly enriched.
Contrary to our expectations, we didn’t find an increased microvessel density in the glands of
cav-1 -/- glands but rather observed that the average number of vessels in both animal models
was the same. Initially, this observation was surprising given that pro-angiogenic factors such
as VEGF and PDGF were reported to be upregulated in the conditioned media from cav-1 -/-
murine mammary fibroblasts [45]. Others have found that cav-1 loss resulted in reduced
angiogenesis. Specifically, it was shown that vessel density and tumor growth were impaired
following subcutaneous injection of melanoma or prostate cancer cells [60, 61]. Based on these
xenograft studies, it’s apparent that cav-1 expression is needed in order to support tumor
angiogenesis. Although cav-1 -/- fibroblasts were reported to produce greater quantities of
pro-angiogenic cytokines, it’s possible that morphological and subsequent functional deficits
in cav-1 -/- endothelial cells prevent these cells from responding to fibroblast-derived pro-
angiogenic factors. While we didn’t investigate morphological or functional differences in cav-
1 -/- and cav-1 +/+ endothelial cells, our results nonetheless support prior work that the loss of
cav-1 doesn’t support enhanced tissue angiogenesis.
Since aberrant patterns of ECM protein expression have been shown to alter mammary epi-
thelial behaviors [31], we sought to determine whether changes in ductal morphology were
evident in cav-1 -/- glands. We found that cav-1 -/- glands exhibited significant increases in
duct numbers as well as greater ductal circumferences and areas than cav-1 +/+ glands. The
ducts of cav-1 -/- animals were further found to not only possess an increased proportion of
proliferating ki67 positive cells but were also noted to exhibit regions of ductal hyperplasia,
characterized by stacked epithelial cells protruding into the lumen. Previously, it has been
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shown that cav-1 -/- KO mice present with mammary gland hyperplasia and actively prolifer-
ating ductal epithelial cells as assessed using bromodeoxyuridine, confirming our findings
[62]. Although the increased proportion of proliferating ductal epithelial cells may explain the
higher ductal numbers, area and hyperplasia, this does not fully support a role for ductal prolif-
eration in circumference. The increased circumference of the ducts in cav-1 -/- glands suggests
that ducts are more elongated. In the pubertal mammary glands of mice, the orientation of col-
lagen fibers determined the directionality of branching ducts, suggesting that collagen organi-
zation imparts important cues to the developing ducts of the mammary glands [63]. It’s
possible that the increased density and organization of collagen in cav-1 -/- animals may simi-
larly provide directional cues for proliferating ductal epithelial cells, supporting the abnormal
outgrowth of these ducts. In addition to collagen, it’s possible that fibronectin is also partici-
pating in aberrant ductal cell behavior. For example, Williams et al [31] demonstrated that the
addition of fibronectin to cultures of mammary epithelial cells grown atop a basement mem-
brane extract stimulated cell proliferation and reversed the acinar morphology, suggesting that
fibronectin disrupts normal ductal architecture. Additional work will be necessary to elucidate
the contributions of collagen and/or fibronectin to aberrant ductal organization.
In conclusion, we have shown that loss of cav-1 increases the expression of fibronectin,
collagen I, tenascin-C and αSMA in murine mammary glands. Furthermore, loss of cav-1
contributed to a significant increase in the number of ducts exhibiting hyperplasia and a
higher proliferation index in addition to ducts having a larger circumference and area. It is
well known that the risk for development of breast cancer increases with increasing mammo-
graphic density [22, 23, 56] and that increases in stromal proteins including fibronectin and
collagen have been implicated in greater tissue stiffness in tumors [64]. Since cav-1 loss
results in increased expression of these proteins in murine mammary glands, it’s likely that
this aberrant ECM may contribute to a situation which favors the early events leading to
tumor initiation. In addition, this abnormal ECM could potentially instigate changes in the
complex signaling cascades within the tissue microenvironment that regulate cell prolifera-
tion, cellular trans-differentiation and matrix deposition and turnover, further favoring an
environment supportive of tumor initiation. As a result, cav-1 expression could potentially
be a useful tumor marker to aid clinicians in better diagnoses, more accurate prognoses, and
may be a powerful tool in determining the best course of therapy for patients. In summary,
our results shed light on a mechanism regulating both the expression of ECM proteins and
ductal organization in the murine mammary gland and have important implications for
our understanding of the events which may take place during the early stages of breast
tumorigenesis.
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